Guardant Health (GH) EBITDA Margin (2017 - 2026)
Guardant Health's (GH) quarterly EBITDA Margin came in at 38.55% in Q2 2026, up 731.0% year-over-year from 4.64% in Q2 2025, and up 4.18% quarter-over-quarter from 40.23% in Q1 2026.
Powered by 
Analysis
Guardant Health (GH) EBITDA Margin (2017 - 2026) Analysis & Trends
Guardant Health has disclosed EBITDA Margin across 10 years of filings, most recently posting 38.55% for Q2 2026.
- In Q2 2026, EBITDA Margin rose 731.0% year-over-year to 38.55%; the TTM figure through Jun 2026 stood at 39.75% (up 1584.0% YoY), while the FY2025 annual figure was 44.53%, up 1550.0% from the prior year.
- EBITDA Margin came in at 38.55% for Q2 2026 at Guardant Health, up from 40.23% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 37.33% in Q3 2025 to a low of 128.34% in Q1 2022.
- Average EBITDA Margin over 5 years is 76.85%, with a median of 61.85% recorded in 2024.
- Year-over-year, EBITDA Margin sank 2431 bps in 2022 and jumped 6497 bps in 2024.
- Over 5 years, EBITDA Margin stood at 115.15% in 2022, then retreated by 11 bps to 127.38% in 2023, then surged by 51 bps to 62.42% in 2024, then jumped by 31 bps to 42.95% in 2025, then grew by 10 bps to 38.55% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 38.55% in Q2 2026, 40.23% in Q1 2026, and 42.95% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Natera | 49.39 Bn | 48.29 Bn | 486.15 Mn | -10.07% |
| 2 | Quest Diagnostics | 27.49 Bn | 26.86 Bn | 1.03 Bn | 15.08% |
| 3 | Labcorp Holdings | 26.51 Bn | 26.37 Bn | 1.11 Bn | 12.10% |
| 4 | Guardant Health | 23.17 Bn | 22.12 Bn | 219.03 Mn | -38.55% |
| 5 | Tempus AI | 12.59 Bn | 11.77 Bn | 274.25 Mn | -19.85% |
| 6 | Caris Life Sciences | 8.01 Bn | 7.22 Bn | 182.38 Mn | 10.21% |
| 7 | Sotera Health | 5.53 Bn | 5.17 Bn | 177.96 Mn | 34.17% |
| 8 | BillionToOne | 4.80 Bn | 4.25 Bn | 77.11 Mn | 5.03% |
| 9 | Adaptive Biotechnologies | 4.40 Bn | 4.05 Bn | 51.39 Mn | -22.04% |
| 10 | iRhythm Holdings | 3.68 Bn | 3.08 Bn | 163.21 Mn | -1.13% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -38.55% |
| Mar 31, 2026 | -40.23% |
| Dec 31, 2025 | -42.95% |
| Sep 30, 2025 | -37.33% |
| Jun 30, 2025 | -45.85% |
| Mar 31, 2025 | -54.57% |
| Dec 31, 2024 | -62.42% |
| Sep 30, 2024 | -61.28% |
| Jun 30, 2024 | -56.77% |
| Mar 31, 2024 | -59.16% |
| Dec 31, 2023 | -127.38% |
| Sep 30, 2023 | -79.38% |
| Jun 30, 2023 | -87.22% |
| Mar 31, 2023 | -104.15% |
| Dec 31, 2022 | -115.15% |
| Sep 30, 2022 | -123.16% |
| Jun 30, 2022 | -119.40% |
| Mar 31, 2022 | -128.34% |
| Dec 31, 2021 | -90.84% |
| Sep 30, 2021 | -113.20% |